CDT · Categories · Form 4

CDT - SEC Form 4 insider transactions

CDT Equity Inc. (CDT) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for CDT

• 26d
  SEC Form 4 filed by Taylor Mark Andrew

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 61d
  Director Farley Chele Chiavacci was granted 10,553 shares, increasing direct ownership by 160% to 17,157 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 125d
  Chief Executive Officer Regan Andrew was granted 224,800 shares (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 216d
  Chief Executive Officer Regan Andrew was granted 1,120,000 shares, increasing direct ownership by 2,545,455% to 1,120,044 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 219d
  CFO Bligh James was granted 480,000 shares, increasing direct ownership by 2,000,000% to 480,024 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 243d
  Director Fry Simon Jeremy was granted 35,000 shares, increasing direct ownership by 1,789% to 36,956 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 243d
  Director Farley Chele Chiavacci was granted 35,000 shares, increasing direct ownership by 1,477% to 37,369 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 243d
  Director Lewis-Hall Freda C was granted 35,000 shares, increasing direct ownership by 1,010% to 38,466 units (SEC Form 4)

  4 - CDT Equity Inc. (0001896212) (Issuer)
• 317d
  Chief Executive Officer Regan Andrew was granted 154,799 shares (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 374d
  Director Charles Faith L. was granted 115,194 shares, increasing direct ownership by 230% to 165,238 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 389d
  Director Lewis-Hall Freda C was granted 47,612 shares, increasing direct ownership by 1,087% to 51,991 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 389d
  Director Fry Simon Jeremy was granted 29,354 shares, increasing direct ownership by 1,468% to 31,354 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 389d
  Director Farley Chele Chiavacci was granted 32,022 shares, increasing direct ownership by 911% to 35,537 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 389d
  Director Charles Faith L. was granted 46,629 shares, increasing direct ownership by 1,365% to 50,044 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 492d
  SEC Form 4 filed by Director Lewis-Hall Freda C

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 492d
  SEC Form 4 filed by Director Farley Chele Chiavacci

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 492d
  SEC Form 4 filed by Director Charles Faith L.

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 492d
  SEC Form 4 filed by Director Fry Simon Jeremy

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 522d
  SEC Form 4 filed by Chief Executive Officer Tapolczay David

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 522d
  Director Lewis-Hall Freda C was granted 437,976 shares (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 522d
  SEC Form 4 filed by Interim CFO Bligh James

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 522d
  Director Charles Faith L. was granted 341,594 shares (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 522d
  Director Farley Chele Chiavacci was granted 299,238 shares, increasing direct ownership by 572% to 351,510 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 566d
  Large owner Nirland Ltd sold $393,439 worth of shares (3,808,000 units at $0.10) (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 571d
  Large owner Nirland Ltd sold $297,644 worth of shares (2,600,000 units at $0.11) (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 584d
  Director Regan Andrew disposed of 1,100,000 shares, acquired 1,100,000 shares and sold $4,592,487 worth of shares (15,301,068 units at $0.30) (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 684d
  Director Farley Chele Chiavacci was granted 37,272 shares, increasing direct ownership by 248% to 52,272 units (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 684d
  Interim CFO Bligh James was granted 37,272 shares (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 711d
  Sragovicz Adam returned 74,545 units of Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4)

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 711d
  SEC Form 4 filed by Mcnealey Jennifer Isacoff

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 732d
  SEC Form 4 filed by Lewis-Hall Freda C

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 732d
  SEC Form 4 filed by Tapolczay David

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
• 732d
  SEC Form 4 filed by Farley Chele Chiavacci

  4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

Other CDT categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends